Gritstone Bio Inc Revenue Growth Rates (GRTS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Gritstone Bio Inc   (NASDAQ: GRTS)
 

GRTS's Revenue Growth by Quarter and Year

Gritstone Bio Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GRTS Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.92
1st Quarter March 1.74
FY 2.66

GRTSs Annual Revenue
Gritstone Bio Inc 's Revenue in the fiscal year 2023 $ 16.34 millions
Gritstone Bio Inc 's Revenue in the fiscal year 2022 $ 19.95 millions
Gritstone Bio Inc 's Revenue in the fiscal year 2021 $ 48.21 millions
Gritstone Bio Inc 's Revenue in the fiscal year 2020 $ 4.04 millions
Gritstone Bio Inc 's Revenue in the fiscal year 2019 $ 4.37 millions




GRTS Revenue second quarter 2024 Y/Y Growth Comment
Gritstone Bio Inc reported drop in Revenue in the second quarter 2024 by -53.01% to $ 0.92 millions, from the same quarter in 2023.
The fall in the second quarter 2024 Gritstone Bio Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 238.48%.

Looking into second quarter 2024 results within Biotechnology & Pharmaceuticals industry 40 other companies have achieved higher Revenue growth. While Gritstone Bio Inc ' s Revenue meltdown of -53.01% ranks overall at the positon no. 3134 in the second quarter 2024.


GRTS Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 143.66 % 39.22 % 126.67 %
3rd Quarter September - -48.01 % 15.71 % 177.66 %
2nd Quarter June -53.01 % -64.17 % 92.61 % 479.59 %
1st Quarter March -28.69 % -66.06 % -81.88 % 3050 %
FY   - -18 % -58.63 % -

Financial Statements
Gritstone Bio Inc 's second quarter 2024 Revenue $ 0.92 millions GRTS's Income Statement
Gritstone Bio Inc 's second quarter 2023 Revenue $ 1.96 millions Quarterly GRTS's Income Statement


GRTS Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 561.15 % 41.06 % 17.24 %
3rd Quarter September - -19.9 % -44.79 % -8.1 %
2nd Quarter June -47.07 % -19.67 % -23.92 % -92.84 %
1st Quarter March -83.24 % -42.72 % 134.97 % 2840 %
FY (Year on Year)   - -18 % -58.63 % -


Back to GRTS Growth rate Comparisons >> Back to GRTS Growth rate Comparisons >>


Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #41
Healthcare Sector #432
Overall #3134

Revenue Y/Y Growth Statistics
High Average Low
1201.37 % 238.48 % -63 %
(Sep 30 2021)   (Mar 31 2022)
Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #41
Healthcare Sector #432
Overall #3134
Revenue Y/Y Growth Statistics
High Average Low
1201.37 % 238.48 % -63 %
(Sep 30 2021)   (Mar 31 2022)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Gritstone Bio Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2844.58 % 156.98 % -92.84 %
(Mar 31 2021)  


GRTS's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2024 Gritstone Bio Inc disclosed fall in Revenue from the first quarter by -47.07% to $ 0.92 millions, from $ 1.74 millions achived in the previous reporting period.

But that's not important problem, as Gritstone Bio Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 58 other companies have achieved higher Revenue quarter on quarter growth. While Gritstone Bio Inc 's Revenue growth quarter on quarter, overall rank is 3648.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #59
Healthcare Sector #555
Overall #3648
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #59
Healthcare Sector #555
Overall #3648
Revenue Q/Q Growth Statistics
High Average Low
2844.58 % 156.98 % -92.84 %
(Mar 31 2021)  


GRTS's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2024 Gritstone Bio Inc disclosed fall in Revenue from the first quarter by -47.07% to $ 0.92 millions, from $ 1.74 millions achived in the previous reporting period.

But that's not important problem, as Gritstone Bio Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 58 other companies have achieved higher Revenue quarter on quarter growth. While Gritstone Bio Inc 's Revenue growth quarter on quarter, overall rank is 3648.


Gritstone Bio Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)
Cumulative Revenue 12 Months Ending $ 14.61 $ 15.64 $ 16.34 $ 10.23 $ 11.68
Y / Y Revenue Growth (TTM) 25.07 % 2.93 % -18.05 % -45.46 % -36.31 %
Year on Year Revenue Growth Overall Ranking # 3402 # 0 # 0 # 2570 # 3523
Seqeuential Revenue Change (TTM) -6.61 % -4.29 % 59.84 % -12.46 % -23.14 %
Seq. Revenue Growth (TTM) Overall Ranking # 3228 # 0 # 0 # 1496 # 1137


Cumulative Revenue growth Comment
Although Gritstone Bio Inc 's Annual Revenue growth year on year were below company's average 238.48% , Revenue announced in the Jun 30 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 25.07% year on year, from 2.93% in Mar 31 2024.

In the Healthcare sector 476 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3402.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 42
Healthcare Sector # 477
Overall # 3402

Revenue TTM Y/Y Growth Statistics
High Average Low
1201.37 %
 238.48 %
-63 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 42
Sector # 454
S&P 500 # 3228
Cumulative Revenue growth Comment
Although Gritstone Bio Inc 's Annual Revenue growth year on year were below company's average 238.48% , Revenue announced in the Jun 30 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 25.07% year on year, from 2.93% in Mar 31 2024.

In the Healthcare sector 476 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3402.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 42
Healthcare Sector # 477
Overall # 3402

Revenue TTM Y/Y Growth Statistics
High Average Low
1201.37 %
238.48 %
-63 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 42
Sector # 454
S&P 500 # 3228




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GRTS's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2024
Organon and Co -0.06%$ -0.062 millions
Royalty Pharma Plc-0.17%$ -0.174 millions
Repligen Corp-0.21%$ -0.207 millions
Whitehawk Therapeutics Inc -0.37%$ -0.371 millions
3m Company-0.45%$ -0.446 millions
T2 Biosystems Inc -0.61%$ -0.611 millions
Hcw Biologics Inc -0.63%$ -0.635 millions
Enhabit Inc -0.65%$ -0.648 millions
Sonoma Pharmaceuticals Inc -1.05%$ -1.050 millions
Encision Inc -1.36%$ -1.358 millions
Vaso Corporation-1.40%$ -1.399 millions
Teladoc Health Inc -1.53%$ -1.527 millions
Zimvie Inc -1.55%$ -1.549 millions
Alpha Pro Tech Ltd -1.65%$ -1.645 millions
Novavax inc -2.11%$ -2.107 millions
Agile Therapeutics Inc-2.23%$ -2.232 millions
Fresenius Medical Care Ag-2.33%$ -2.330 millions
Avantor Inc -2.36%$ -2.357 millions
Aspira Women s Health inc -2.81%$ -2.810 millions
Viatris Inc -3.11%$ -3.113 millions
Catheter Precision Inc -3.13%$ -3.125 millions
Nrc Health-3.15%$ -3.153 millions
Akoya Biosciences Inc -3.16%$ -3.158 millions
Neuronetics Inc -3.55%$ -3.547 millions
Mettler toledo International Inc -3.60%$ -3.601 millions
Prestige Consumer Healthcare Inc -4.18%$ -4.181 millions
Dentsply Sirona Inc -4.28%$ -4.280 millions
Waters Corporation-4.33%$ -4.327 millions
Accelerate Diagnostics Inc -4.39%$ -4.394 millions
Envista Holdings Corporation-4.50%$ -4.499 millions


About Gritstone Bio Inc Revenue Growth Rates (GRTS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Gritstone Bio Inc (CIK 1656634).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-24-096211
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Gritstone Bio Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.